Rashid Sayyid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rashid sayyid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rashid Sayyid Today - Breaking & Trending Today

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib. ....

United States , Sumantak Pal , Sumanta Pal , American Society Of Clinical Oncology , Department Of Medical Oncology , Society Of Urologic Oncology , University Of Toronto , Therapeutics Research , City Of Hope Comprehensive Cancer Center , Clinical Oncology , Annual Meeting , South America , North America , Medical Oncology , Hope Comprehensive Cancer Center , Rashid Sayyid , Urologic Oncology , Clinical Fellow ,

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

Discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings. ....

United States , New York , Memorial Sloan Kettering Cancer Center , Karen Autio , Karena Autio , European Association Of Urology , American Society Of Clinical Oncology , Oncology Group , National Comprehensive Cancer Network , University Of Toronto , Society Of Urologic Oncology , Genitourinary Oncologist Early Drug Development Specialist , American Urological Association , Clinical Oncology , Annual Meeting , Prostate Cancer Consensus Conference , European Association , Southwest Oncology Group , Assistant Attending Physician , Genitourinary Oncologist , Early Drug Development Specialist , Rashid Sayyid , Urologic Oncology , Clinical Fellow , Comprehensive Treatment , Oligometastatic Cancers ,

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). ....

United States , Georgetown University , District Of Columbia , Michael Atkins , Michaelb Atkins , University Of Toronto , Georgetown Lombardi Comprehensive Cancer Center , Department Of Medical Oncology , Database Consortium , Georgetown University Medical Center , Merck Sharp Dome , Society Of Urologic Oncology , International Metastatic , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Deputy Director , Scholl Professor , Vice Chair , Medical Oncology , Rashid Sayyid , Urologic Oncology , Clinical Fellow ,

ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers. ....

United States , South Korea , Soult Ukpyolsi , Jae Lyun Lee , Md Anderson Cancer Center , Society Of Urologic Oncology , American Society Of Clinical Oncology , University College Of Medicine , Asan Medical Center , University Of Toronto , Clinical Oncology , Annual Meeting , University College , Rashid Sayyid , Urologic Oncology , Clinical Fellow , Anderson Cancer Center , Patients With Relapsed , Metastatic Malignant Urachal ,

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial.

Advanced adrenocortical carcinoma, camrelizumab, Apatinib, Camrelizumab plus Apatinib. ....

United States , Zhigong Wei , Society Of Urologic Oncology , American Society Of Clinical Oncology , University Of Toronto , Sichuan University , Department Of Biotherapy , Cancer Center , Clinical Oncology , Annual Meeting , West China Hospital , Rashid Sayyid , Urologic Oncology , Clinical Fellow , Advanced Adrenocortical ,